Trastuzumab is a fully humanized IgG1 mAb targeting the extracellular domain of the HER2 that has demonstrated clinical efficacy in both early and advanced BC (92, 93), metastatic gastric cancer (GC) (94), and urothelial cancer (UC) (95) with overexpressed HER2. Here, ERBB2 is linked to breast cancer.